Journal article
Patient-derived xenograft models of breast cancer and their predictive power
JR Whittle, MT Lewis, GJ Lindeman, JE Visvader
Breast Cancer Research | Published : 2015
Abstract
Despite advances in the treatment of patients with early and metastatic breast cancer, mortality remains high due to intrinsic or acquired resistance to therapy. Increased understanding of the genomic landscape through massively parallel sequencing has revealed somatic mutations common to specific subtypes of breast cancer, provided new prognostic and predictive markers, and highlighted potential therapeutic targets. Evaluating new targets using established cell lines is limited by the inexact correlation between responsiveness observed in cell lines versus that elicited in the patient. Patient-derived xenografts (PDXs) generated from fresh tumor specimens recapitulate the diversity of breas..
View full abstractGrants
Awarded by State Government of Victoria
Funding Acknowledgements
The authors thank P Maltezos for assistance in preparing the figures. This work was supported by the Australian National Health and Medical Research Council (NHMRC) grants # 1016701 and # 1040978, the NHMRC IRIISS, and the Victorian State Government through Operational Infrastructure Support. MTL is supported by Susan G. Komen Foundation grant KG120001, NIH/NCI grant U54 CA149196, and Baylor College of Medicine Cancer Center grant P30 CA125123. GJL is supported by a NHMRC Fellowship (# 637307). JEV is supported by an Australia Fellowship.